Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome.

Abstract

A patient with a potassium wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome is described. A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo. The diagnosis of a functional Bartter's syndrome was concluded following evaluation of serial plasma renins, aldosterone levels, and urinary electrolytes. Evidence is suggestive that a subpopulation of patients receiving chemotherapy may develop a functional Bartter's syndrome, and it is important to consider this diagnosis in patients who develop hypokalemia subsequent to chemotherapy introduction.

• Authors: I H Lieber, S D Stoneburner, M Floyd, W L McGuffin
• Journal: Cancer (Cancer) Vol. 54 Issue 5 Pg. 808-10 (Sep 01 1984) ISSN: 0008-543X [Print] United States
• PMID: 6204737 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bleomycin
• Aldosterone
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Renin
• Magnesium
• Prednisone

Topics

• Aldosterone (blood)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bartter Syndrome (blood, chemically induced, urine)
• Bleomycin (administration & dosage, adverse effects)
• Cyclophosphamide (administration & dosage, adverse effects)
• Diagnosis, Differential
• Doxorubicin (administration & dosage, adverse effects)
• Female
• Humans
• Hyperaldosteronism (chemically induced)
• Hypokalemia (blood, chemically induced, urine)
• Lymphoma, Large B-Cell, Diffuse (blood, drug therapy, urine)
• Magnesium (urine)
• Middle Aged
• Prednisone (administration & dosage, adverse effects)
• Renin (blood)
• Vincristine (administration & dosage, adverse effects)